Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV001782262 | SCV002016623 | likely pathogenic | Hermansky-Pudlak syndrome 1 | 2021-02-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002034595 | SCV002267787 | likely pathogenic | not provided | 2021-03-17 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. Disruption of this splice site has been observed in individual(s) with Hermansky-Pudlak syndrome (PMID: 29941477). This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 18 of the HPS1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in HPS1 are known to be pathogenic (PMID: 12442288, 16185271). |
Baylor Genetics | RCV001782262 | SCV004199933 | likely pathogenic | Hermansky-Pudlak syndrome 1 | 2023-08-23 | criteria provided, single submitter | clinical testing |